A gene therapy developer focused on treating retinal diseases is being launched with £96 million (about $120 million) in Series A financing and a pipeline anchored by a later-stage X-linked retinitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback